Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3416-3422

  Hingorani, Pooja ^a   Zhang, Wendong ^b   Gorlick, Richard ^b   Kolb, E Anders ^c  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; DASATINIB; FOCAL ADHESION KINASE; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ONCOGENE SRC; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, SCID; OSTEOSARCOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149192409     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1657     Document Type: Article

References (31)

1. Meyers PA, Gorlick RG. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989
2. Maa MC, Leu TH, McCarley DJ, et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis byc -Src: implications for the etiologyof multiple human cancers. Proc Natl Acad Sci U S A 1995;92:6981-6985
3. Mori S, Ronnstrand L, Yokote K, et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF-β receptor; involvement in the interaction with Src familyty rosine kinases. EMBO J 1993;12:2257-2264 (Pubitemid 23194175)
4. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004;23:7928-7946 (Pubitemid 39468852)
5. Brown MT, Cooper JA. Regulation, substrates and function of src. Biochim Biophys Acta 1996;12:121-149
6. +-ATPase. J Biol Chem 2000;8:27832-27837
7. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activityof Stat-3 related protein in cells transformed bythe Src oncoprotein. Science 1995;269:81-83
8. Munshi N, Groopman GE, Gill PS, et al. c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. J Immunol 2000;164:1169-1174 (Pubitemid 30067226)
9. Yeatman TJ. A renaissance for Src. Nat Rev Cancer 2004;4:470-480 (Pubitemid 38745532)
10. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541 (Pubitemid 43882349)
11. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150 (Pubitemid 46890528)
12. Nam S, Kim D, Cheng JQ, et al. Action of the Src familykin ase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189 (Pubitemid 41507982)
13. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932 (Pubitemid 41428750)
14. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548 (Pubitemid 43927102)
15. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 2007;67:2800-2808 (Pubitemid 46548969)
16. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005;22:319-329 (Pubitemid 41374288)
17. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib bythe pediatric preclinical testing program. Pediatr Blood Cancer; Epub 2007.
18. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-2338 (Pubitemid 44497517)
19. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;20:5636-5642
20. Summy JM, Gallick GE. Src family of kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-358 (Pubitemid 36791891)
21. Summy JM , Gallick GE. Treatment of advanced tumors: Src reclaims center stage. Clin Cancer Res 2006;12:1398-1401
22. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-972 (Pubitemid 43327748)
23. Jallal H, Valentino ML, Chen G, et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vivo and in vivo. Cancer Res 2007;15:1580-1588 (Pubitemid 46383382)
24. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10:201-204 (Pubitemid 38581790)
25. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-2411 (Pubitemid 40490152)
26. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-186 (Pubitemid 38524889)
27. Ogino W, Takeshima Y, Mori T, et al. High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis. J Pediatr Hematol Oncol 2007;29:435-439 (Pubitemid 47026243)
28. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-2567 (Pubitemid 40569454)
29. Kim SY, Lee SH, Midura BV, et al. Inhibition of CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis; Epub 2007.
30. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
31. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin like growth-factor-1 receptor specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2006;12:3532-3540